Compare Inovio Pharmaceuticals Inc (INO) vs Paychex, Inc. (PAYX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Inovio Pharmaceuticals Inc vs Paychex, Inc. — how do they compare? Inovio Pharmaceuticals Inc trades at $0.76 (market cap $78.55M), while Paychex, Inc. trades at $119.37 (market cap $43.14B). The key difference: Paychex, Inc. is far larger — about 549.2× Inovio Pharmaceuticals Inc's market cap, and Paychex, Inc. pays a 3.92% dividend while Inovio Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| INO | PAYX | |
|---|---|---|
Market Cap | $78.55M | $43.14B |
Sector | Health | Industrials |
52-Week High | $2.87 | $140.81 |
52-Week Low | $0.66 | $85.57 |
Enterprise Value | $49.56M | $46.63B |
Dividend Yield | — | 3.92% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INO trades at $0.76, up 2.74% today, but remains in a bearish technical trend. The company shows minimal revenue of $65K against high operating losses, with a net income margin of -130,000%. Recent quarterly EPS has beaten expectations. Analyst consensus is bullish with a $3.25 price target, but the stock faces significant fundamental challenges including negative cash flow and high valuation multiples.
The outlook hinges on FDA approval of INO-3107 in October 2026, a binary event that could drive substantial upside. However, persistent cash burn, negative profitability, and ongoing shareholder litigation present high risks. Investors should weigh the potential catalyst against the company's weak financial health and operational execution challenges.
Paychex (PAYX) trades at $119.93, down 1.03% today, with a bullish technical outlook and strong profitability. Recent quarters show consistent earnings beats, with Q2 2026 EPS expected at $1.33. The company maintains robust margins, including a 27.03% net income margin, and pays a steady dividend of $1.19 quarterly. Cash flow trends indicate operational strength, though 2025 saw significant investing outflows.
The stock presents a mixed outlook: solid fundamentals and dividend appeal are offset by a consensus 'Hold' rating and a price target below the current level. Risks include high valuation multiples and potential economic sensitivity for small business clients. Upside depends on sustained earnings growth and market sentiment shifts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →About Paychex, Inc.
Paychex is a leading provider of payroll, human capital management, and insurance solutions servicing small and midsize clients primarily in the United States. The company, established in 1979, services over 730,000 clients and pays over 1 in 12 U.S. private-sector workers. Alongside its traditional payroll services, Paychex offers HCM solutions such as benefits administration and time and attendance software, as well as human resources outsourcing and insurance agency services.
Read more on PAYX →
